



00-000000000



231810

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

**Patient Name:** \_\_\_\_\_ **Date:** 6/13/2025  
**Patient ID:** \_\_\_\_\_ **Patient Date Of Birth:** \_\_\_\_\_  
**Patient Group No:** \_\_\_\_\_ **Patient Phone:** \_\_\_\_\_ **Physician Name:** \_\_\_\_\_  
**NPI#:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_  
**Physician Office Telephone:** \_\_\_\_\_

**Physician Office Address:** \_\_\_\_\_

**Drug Name (specify drug)** \_\_\_\_\_

**Quantity:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **Strength:** \_\_\_\_\_

**Route of Administration:** \_\_\_\_\_ **Expected Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_

**Comments:** \_\_\_\_\_

**Please check the appropriate answer for each applicable question.**

1. What is the diagnosis?
  - Cystic fibrosis (If checked, go to 2) ☐
  - Other, please specify. (If checked, no further questions) ☐
2. Will the requested drug be used in combination with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (e.g., Kalydeco, Trikafta)? **Y** ☐ **N** ☐
3. Is the requested drug being prescribed by or in consultation with a pulmonologist? **Y** ☐ **N** ☐
4. Is the patient currently receiving therapy with the requested drug? **Y** ☐ **N** ☐
5. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?
  - Yes (If checked, go to 7) ☐
  - No (If checked, go to 6) ☐
  - Unknown (If checked, go to 7) ☐
6. Is the patient experiencing a benefit from therapy with the requested drug as evidenced by disease stability or disease improvement (e.g., improvement in FEV1 from baseline)? **Y** ☐ **N** ☐
7. Was genetic testing performed to detect a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?
  - Yes (If checked, go to 8) ☐
  - No (If checked, no further questions) ☐
  - Unknown (If checked, no further questions) ☐
8. Is the patient homozygous for the F508del mutation (positive for the F508del mutation on both alleles) in the CFTR gene? ACTION REQUIRED: If yes, attach genetic testing report.
  - Yes (If checked, go to 10) ☐
  - No (If checked, go to 9) ☐

Unknown (If checked, go to 9)

☐

ACTION REQUIRED: Submit supporting documentation

9. Was the genetic test positive for any mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene? ACTION REQUIRED: If yes, please specify genetic mutation AND attach genetic test.

Yes - Please specify the mutation. (If checked, go to 10)

☐

---

No (If checked, no further questions)

☐

ACTION REQUIRED: Submit supporting documentation

10. Is the patient 6 years of age or older?

Y ☐

N ☐

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

---

**Prescriber (Or Authorized) Signature and Date**

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to [www.caremark.com/epa](http://www.caremark.com/epa).